CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (NCT06690775)

🧪 Interventions in This Study

• TORL-1-23 (DRUG)
• TORL-1-23 (DRUG)
• TORL-1-23 (DRUG)
• Pegfilgrastim (drug) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (66 Sites)

Showing the first 25 of 66 sites.

• Mayo Clinic Hospital — Phoenix, Arizona
• SCRI - Arizona Oncology Associates, PC-HOPE — Tucson, Arizona
• City of Hope National Medical Center — Duarte, California
• Providence St. Jude Medical Center — Fullerton, California
• UCLA - JCCC Clinical Research Unit — Los Angeles, California
• Stanford Cancer Center — Palo Alto, California
• SCRI - Sansum Clinic — Santa Barbara, California
• Smilow Cancer Hospital at Yale - New Haven — New Haven, Connecticut
• Mayo Clinic Florida — Jacksonville, Florida
• Winship Cancer Institute, Emory University — Atlanta, Georgia
• University of Chicago Medical Center — Chicago, Illinois
• SCRI - Maryland Oncology Hematology, P.A. — Annapolis, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• SCRI - Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota
• University of Minnesota — Minneapolis, Minnesota
• Mayo Clinic — Rochester, Minnesota
• Washington University — St Louis, Missouri
• Rutgers Cancer Institute — New Brunswick, New Jersey
• Duke Cancer Center — Durham, North Carolina
• The James Cancer Hospital and Solove Research Institute - Ohio State University — Columbus, Ohio
• Stephenson Cancer Center at the University of Oklahoma — Oklahoma City, Oklahoma
• SCRI - Northwest Cancer Specialists, P.C. — Portland, Oregon
• SCRI - Alliance Cancer Specialists, PC — Doylestown, Pennsylvania
• University of Pennsylvania — Philadelphia, Pennsylvania
• SCRI - Texas Oncology — Fort Worth, Texas

📞 Contact the Study Coordinator

Phone: (310) 348-9636

Email: CATALINA-2-Study@torlbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Epithelial Ovarian Cancer

• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Phoenix, Arizona
• Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian — Chapel Hill, North Carolina
• Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) — Birmingham, Alabama
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) — Glendale, California
• T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors — Pittsburgh, Pennsylvania
• EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma — Seattle, Washington

Explore by condition: All Epithelial Ovarian Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.